id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-347293-fp8phk0p	Kearns, Donovan G.	Assessing The Risk of Adalimumab Use For Hidradenitis Suppurativa During The COVID-19 Pandemic	2020-07-28		.txt	text/plain	613	39	53	With limited real-life data from COVID-19 infection in patients with hidradenitis suppurativa (HS) receiving adalimumab, we can use previous drug trials to extrapolate the potential risk to patients, based upon the change in infection rate when compared to placebo. At the end of period 1, infection developed in 24.8% and 25.2% of those receiving adalimumab QW, compared to 28.3% and 32.5% of patients receiving placebo, in PIONEER 1 and 2, respectively. At the end of period 2, infection occurred in 29.2% and 35.3% of patients receiving adalimumab QW, 25.0 and 35.8 of patients receiving the medication Q2W and 32.7 and 25.5% of patients in the placebo control group, in PIONEER 1 and 2, respectively. However, the findings support the notion that healthy HS patients, without risk factors, who use adalimumab during the COVID-19 pandemic are not predisposed to infection or nasopharyngitis ( Table 1) .	./cache/cord-347293-fp8phk0p.txt	./txt/cord-347293-fp8phk0p.txt